We then tested whether knockdown of hepatocyte Fendrr would prevent liver fibrosis by intravenously injecting the lentivirus 2 days prior to the first injection of CCl4. By 4 weeks of CCl4-treatment, the CCl4-treated liver displayed a typical feature of fibrosis, whereas delivery of the Fendrr shRNA lentivirus greatly alleviated the severity of fibrosis and reduced the fibrotic area and hepatic hydroxyproline content (Fig. 3, A–C). The gene discussed is FENDRR; the disease is Hepatic fibrosis.